Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-29T18:37:26.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide NIH announcement about the terminology transition appears above the unavailable study record.
    Difference
    1%
    Check dated 2026-10-22T22:42:44.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 while the study page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-15T21:53:16.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-08T22:01:33.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with a basic header/footer and a Home link, indicating access to the study record is blocked. This places the page in an error state rather than loading its usual study details.
    Difference
    0.5%
    Check dated 2026-10-01T20:58:15.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    Deleted key study documents and metadata from the MARIPOSA-2 study page, including the Statistical Analysis Plan, Study Protocol, and IPD sharing information. Related terms and metadata were also removed to reduce access to protocol details and data-sharing resources on the page.
    Difference
    17%
    Check dated 2026-09-24T20:59:01.000Z thumbnail image

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.